ClinicalTrials.gg
CompletedNCT04428684Updated Jun 11, 2020

COMPARISON OF A NEW FORMULATION OF GOSERELIN (Pepti 3.6 mg) to Zoladex® 3.6 mg

A Phase 1 interventional study of Pepti 3.6 mg in Dysfunctional Uterine Bleeding, sponsored by Peptigroupe Inc.. Completed at 5 sites in Ukraine. Open to female participants. Per ClinicalTrials.gov, last updated 2020-06-11.

Sponsored by Peptigroupe Inc. · Phase 1, Interventional, and Other

From the registry’s dates

  • Registered 1 year 7 months after the study started (first participant enrolled Oct 2018, registered Jun 2020).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
80
Allocation
Randomized
Sex
Female
01

Study summary

The comparator drug (Zoladex 3.6 mg) is approved for use as a thinning agent for the endometrium prior to endometrial ablation. The dosing recommendation is one or two depots with each depot given four weeks apart. When two depots are administered, surgery should be performed within two to four weeks following administration of the second depot.

Read the detailed description

The primary objective of the study is to demonstrate non-inferiority of a generic formulation of goserelin 3.6 mg as compared to Zoladex ® 3.6 mg on endometrial thinning prior to surgery. The study is an open label, multicenter, prospective, parallel group randomized study.

Blind for Sponsor, ultrasound assessment, testing labs and statistician, the study will be performed in premenopausal women with dysfunctional uterine bleeding (DUB) eligible for endometrial ablation. Patients will be randomized in a 1 to 1 ratio to receive either the Peptigroupe test product (Pepti 3.6 mg) or Zoladex® 3.6 mg for a treatment of 8 weeks (two injections).

Ultrasonic measurement of endometrial thickness will be performed on screening and on days 0 (pre-injection), 28 (pre-injection) and 42 (pre surgical procedure).

The pharmacodynamics profile will be tabulated at the end of the study on the basis of the following data:

  1. Estradiol
  2. LH and FSH as additional information on hormone response

Goserelin safety profile will be assessed throughout the study on the basis of the following assessments:

  1. Treatment-emergent AEs
  2. Physical examinations
  3. Vital signs
  4. 12-Lead ECG
  5. Laboratory parameters (i.e., biochemistry, haematology, and urinalysis)
02

Conditions studied

  • Dysfunctional Uterine Bleeding

Browse trials for

03

In context

Metrorrhagia

153 studies on the registry are indexed under Metrorrhagia; 35 are open to participants now.

This study's enrollment of 80 is below the median of 100 across 115 interventional studies indexed under Metrorrhagia.

Browse Metrorrhagia studies →

Lead sponsor

This is the only study on the registry with Peptigroupe Inc. as lead sponsor.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Be pre-Menopausal females with regular menstrual cycles and > 30 years of age 2. Premenopausal at enrollment as determined by FSH measurement ≤ 60 IU/mL. 3. Endometrial thickness at pre-treatment less than 20 mm. 4. Diagnosis of Dysfunctional Uterine Bleeding and requiring endometrial ablation 5. Tumour negative cytology and histology 6. Appropriate sized uterus with no anatomic pathologies 7. Patient is not pregnant and does not wish to become pregnant in the future 8. Patient is willing to use a non-hormonal method during the study, nor an intra-uterine device 9. Patient has no endocrine disorders, is not receiving hormonal therapies or non-steroidal anti-inflammatory medication. (prophylactic antibiotics can be administered according to the usual practice of the investigator) 10. Have the ability to understand the requirements of the study and is willing to provide written 11. Agree to abide by the study restrictions and return for the required assessments 12. Only patients which can be discontinued safely from medications discussed below in section 7.4 can be included in the study.

Exclusion criteria

-

Exclusion Criteria:

  1. Be pregnant or have desire to conceive
  2. Have abnormal endometrial cytology as confirmed by histology
  3. Have active endometritis
  4. Have active pelvic inflammatory disease
  5. Have active sexually transmitted disease (STD), at the time of ablation. Note: Treatment of STD documented in the chart serves as sufficient evidence of infection resolution. Patient may be considered for study enrollment.
  6. Presence of bacteremia, sepsis, or other active systemic infection
  7. Have active infection of the genitals, vagina, cervix, uterus or urinary tract at the time of inclusion
  8. Known/suspected gynecological within the past 5 years
  9. Known clotting defects or bleeding disorders
  10. Untreated/unevaluated cervical dysplasia
  11. Known/suspected abdominal/pelvic cancer
  12. Atypical Hyperplasia
  13. Prior uterine surgery (except low segment cesarean section) that interrupts the integrity of the uterine wall (e.g., myomectomy or classical cesarean section
  14. Currently on medications that could thin the myometrial muscle, such as long-term use (except inhaler or nasal therapy for asthma)
  15. Currently on anticoagulants
  16. Have a known to gonadotropin releasing hormone (GnRH), GnRH agonists, any LHRH agonists (e.g., leuprolide (Lupron®), goserelin ( Zoladex®) etc.) or to the PLGA polymers contained in the study formulation
  17. Have a severe liver disease (e.g., cirrhosis, chronic active hepatitis or chronic persistent hepatitis) or has persistent , AST ˃ 2 X , serum creatinine ˃ 2 X ULN, serum ˃ 2 X ULN
  18. Have received an drug or participated in a clinical trial within the last 30 days
  19. Have clinically serious and/or unstable concurrent infection, medical illnesses or conditions that are uncontrolled or whose control, in the opinion of the Investigator, may be jeopardized by participation in this study or by the complications of this therapy
  20. Patients with ˂ 18
  21. Anticoagulated patients with ≥ 2
  22. Patients with a history of , congenital long QT syndrome, electrolyte abnormalities, CHF, or concurrent administration with QT prolonging drugs or QTc ˃450 msec.

    -

Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
80 participants (actual)

Study arms

  • Experimental
    Pepti 3.6 treatment

    Patients treated with goserelin depot 3.6 mg. One injection on Day 0 and a second injection on Day 28

    Drug: Pepti 3.6 mg

  • Active comparator
    Zoladex 3.6 mg treatment

    Patients treated with goserelin depot 3.6 mg. One injection on Day 0 and a second injection on Day 28

    Drug: Pepti 3.6 mg

Interventions

  • Each patient receives one injection of Pepti 3.6mg or Zoladex 3.6mg on Day 0 and a second injection of the same drug given the first time on Day 28. On Day 42 patients undergo endometrial ablation

    Also known as: Zoladex 3.6 mg

06

What researchers measure

Primary outcomes

  1. Non-inferiority in terms of activity of test drug versus comparator

    Non-inferiority of test drug compared to comparator in terms of reduction of the endometrial thickness prior to surgical ablation

    Time frame: 1 year

07

Study locations

5 sites
  • Central Military Hospital
    Kyiv, 01133, Ukraine
  • LLC Medical Center
    Kyiv, 03039, Ukraine
  • Maternity Hospital no 3
    Kyiv, 03148, Ukraine
  • Center for Innovative Medical Technologies of the National Academy of Sciences
    Kyiv, 04053, Ukraine
  • City Clinical Hospital
    Kyiv, 04112, Ukraine
08

References and documents

Individual participant data

Plan to share: No — There is no plan to share IPD with other researchers

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Oct 2018 to primary completion in Apr 2020, 17 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 9, 2020
First posted
Jun 11, 2020
StartActual
Oct 29, 2018
Primary completionActual
Apr 1, 2020
CompletionActual
Jun 7, 2020
Last update
Jun 11, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 11, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04428684
Lead sponsor
Peptigroupe Inc.
Responsible party
Sponsor
First posted
Jun 11, 2020
Start date
Oct 29, 2018
Primary completion
Apr 1, 2020
Completion
Jun 7, 2020
Last update
Jun 11, 2020

Study contacts

Bonabes deRougé, MD
study director · Peptigroupe Inc.
Andrii Zaremba
study chair · Pharmaxi LLC

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Goserelin

Start the discussion